This review investigates the side effects of glucagon-like peptide-1receptoragonists(GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for their efficacy in promotingweightlossamong individuals with obesity. The rationale is rooted in understanding the balance between their therapeutic benefits and associated risks.
The development of glucagon-like peptide1(GLP1)receptoragonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity.
GLP-1receptoragonistswork by targetingGLP-1receptors: increasing insulin, decreasing glucagon and delaying gastric emptying. Originally developed for use in type 2 diabetes mellitus,GLP-1sare increasingly being licensed forweight-lossand other cardiometabolic applications.
Such details provide a deeper understanding and appreciation for Glp-1 Receptor Agonists Involuntary Weight Loss.
DiscontinuingGLP-1RA leads to substantial long-termweightregain, ranging from 60% to 163% of priorweightloss, depending on the type ofGLP-1RA [24]. However, the impact of early discontinuation and subsequentweightregain on dietary behavior, including the potential for disordered eating or (micro)nutrient imbalances, remains unclear.
Glucagon-like peptide-1 (GLP-1)receptoragonists(RAs) have become central in managing obesity and type 2 diabetes, primarily through appetite suppression and metabolic regulation. This review explores the mechanisms underlyingGLP-1RA-inducedweightloss, focusing on central and peripheral pathways. Centrally,GLP-1RAs modulate brain regions controlling appetite, influencing ...
Glucagon-like peptide-1receptoragonists(GLP-1RAs) have transformed obesity management, offering substantialweightlossand metabolic benefits. This review examines their expanding role, evaluating efficacy compared to alternative treatments, emerging indications, ongoing challenges, and future directions. Beyond obesity and type 2 diabetes, the therapeutic potential ofGLP-1RAs extends ...
